nach oben

Erschienen in:

20.08.2018 | Review articles

Effect of ulinastatin on interleukins and pulmonary function in bypass patients: a meta-analysis of randomized controlled trials

verfasst von: G. He, Q. Li, W. Li, Y. Ruan, X. Xiong, X. Song, F. Zeng

Erschienen in: Herz | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Our aim was to evaluate the effect of urinary trypsin inhibitors (UTI) on interleukin, tumor necrosis factor-α (TNF-α), and polymorphonuclear neutrophil elastase (PMNE) levels as well as on pulmonary function in patients undergoing cardiopulmonary bypass.

Materials and methods

We searched the following databases for relevant studies: PubMed, Medline (Ovid SP), Cochrane Library, Wanfang Data, China Biology Medicine Database, Chinese Periodical Database, China Knowledge Resource Integrated Database, and Chinese Clinical Trial Registry. Two investigators independently collected the data and assessed the quality of each study. RevMan 5.3 was used for the meta-analysis.

Results

In total, 15 randomized controlled trials (646 patients) met the inclusion criteria. There was a significant decrease in TNF-α, interleukin-6 (IL-6), IL-8, and PMNE levels at 6 h and 24 h after UTI treatment and an increase in IL-10 levels; additionally, there was a decrease in respiratory index and an improvement in the oxygenation index. Nevertheless, UTI treatment did not affect the length of intensive care unit stay, alveolar–arterial oxygen partial pressure difference, adverse lung events, or hospital mortality. Because of the high heterogeneity of the included trials, the results should be assessed carefully.

Conclusion

UTI treatment can suppress proinflammatory cytokine elevation and upregulate the release of anti-inflammatory mediators, thereby reducing pulmonary injury and improving pulmonary function after cardiopulmonary bypass.

Rossaint J, Berger C, Van Aken H et al (2012) Cardiopulmonary bypass during cardiac surgery modulates systemic inflammation by affecting different steps of the leukocyte recruitment cascade. PLoS ONE 7:e45738PubMedPubMedCentralCrossRef

Yuan SM (2015) Postperfusion lung syndrome: respiratory mechanics, respiratory indices and biomarkers. Ann Thorac Med 10:151–157PubMedPubMedCentralCrossRef

Linder A, Russell JA (2014) An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor. Intensive Care Med 40:1164–1167PubMedCrossRef

Apostolakis EE, Koletsis EN, Baikoussis NG et al (2010) Strategies to prevent intraoperative lung injury during cardiopulmonary bypass. J Cardiothorac Surg 5:1PubMedPubMedCentralCrossRef

Wynne R, Botti M (2004) Postoperative pulmonary dysfunction in adults after cardiac surgery with cardiopulmonary bypass: clinical significance and implications for practice. Am J Crit Care 13:384–393PubMedCrossRef

Gentile LF, Cuenca AG, Efron PA et al (2012) Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg 72:1491–1501PubMedPubMedCentralCrossRef

Huang N, Wang F, Wang Y et al (2013) Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis. J Surg Res 182:296–302PubMedCrossRef

Chen J, Wang J, Su C et al (2016) Urinary trypsin inhibitor attenuates LPS-induced endothelial barrier dysfunction by upregulation of vascular endothelial-cadherin expression. Inflamm Res 65:213–224PubMedCrossRef

Luo Y, Che W, Zhao M (2017) Ulinastatin post-treatment attenuates lipopolysaccharide-induced acute lung injury in rats and human alveolar epithelial cells. Int J Mol Med 39:297–306PubMedCrossRef

10.

Ng CS, Wan S (2012) Limiting inflammatory response to cardiopulmonary bypass: pharmaceutical strategies. Curr Opin Pharmacol 12:155–159PubMedCrossRef

11.

Wang LZ, Luo MY, Zhang JS et al (2016) Effect of ulinastatin on serum inflammatory factors in Asian patients with acute pancreatitis before and after treatment: a meta-analysis. Int J Clin Pharmacol Ther 54:890–898PubMedCrossRef

12.

Rui M, Duan YY, Zhang XH et al (2012) Urinary trypsin inhibitor attenuates seawater-induced acute lung injury by influencing the activities of nuclear factor-kB and its related inflammatory mediators. Respiration 83:335–343PubMedCrossRef

13.

Ren B, Wu H, Zhu J et al (2006) Ulinastatin attenuates lung ischemia-reperfusion injury in rats by inhibiting tumor necrosis factor alpha. Transplant Proc 38:2777–2779PubMedCrossRef

14.

Zhang Y, Zeng Z, Cao Y et al (2014) Effect of urinary protease inhibitor (ulinastatin) on cardiopulmonary bypass: a meta-analysis for China and Japan. PLoS ONE 9:e113973PubMedPubMedCentralCrossRef

15.

Pang XY, Fang CC, Chen YY et al (2016) Effects of ulinastatin on perioperative inflammatory response and pulmonary function in cardiopulmonary bypass patients. Am J Ther 23:e1680–e1689PubMedCrossRef

16.

Shi XQ, Wang YH, Li JQ et al (2013) Protective effect of ulinastatin on pulmonary function after cardiopulmonary bypass. Sichuan Da Xue Xue Bao Yi Xue Ban 44:752–755PubMed

17.

Nakanishi K, Takeda S, Sakamoto A et al (2006) Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 34:1351–1357PubMedCrossRef

18.

Xu HY, Rong XS, Wang DP et al (2017) Effect of urinary trypsin inhibitor on inflammatory cytokines and organ function in patients with cardiopulmonary bypass. Eur Rev Med Pharmacol Sci 21:2220–2225PubMed

19.

Zhou Q, Wang G, Gao C et al (2010) Effect of ulinastatin on perioperative inflammatory response to coronary artery bypass grafting with cardiopulmonary bypass. Zhong Nan Da Xue Xue Bao Yi Xue Ban 35:107–110PubMed

20.

Bao HJ, Gao BS, Li TC (2006) Influence of ulinastatin on TNF-α, IL-6, IL-8 in patients of mitral valve replacement. Shandong Yi Kan 46(6):6–7

21.

Wang HM, Dai AL, He W et al (2006) Protective effect of ulinastatin on pulmonary function after cardiopulmonary bypass. Chin J Postgrad Med 29(6):34–35

22.

Chen C, Li LM, Cao MJ et al (2007) Influence of ulinastatin on lungs in cardopulmonary bypass patients. Chin J Cardiovasc Med 5(2):109–112

23.

Yu XY, Fan LL (2009) Effects of different doses of ulinastatin on inflammatory response and pulmonary function after cardiopulmonary bypass. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 21:664–667PubMed

24.

Xu CE, Zou CW, Zhang MY et al (2013) Effects of high-dose ulinastatin on inflammatory response and pulmonary function in patients with type-A aortic dissection after cardiopulmonary bypass under deep hypothermic circulatory arrest. J Cardiothorac Vasc Anesth 27:479–484PubMedCrossRef

25.

Bingyang J, Jinping L, Mingzheng L et al (2007) Effects of urinary protease inhibitor on inflammatory response during on-pump coronary revascularisation. Effect of ulinastatin on inflammatory response. J Cardiovasc Surg (Torino) 48:497–503

26.

Lv M, Zhang XH, Zhang BM et al (2009) Effects of ulinastain on protecting pulmonary in cardiopulmonary bypass. Chin J Lab Diagn 13(3):369–371

27.

Lin BS, Zhang XH, Zhang BM et al (2008) Effects of ulinastain on protecting pulmonary in elderly patients of mitral valve replacement. Chin J Gerontol 28(24):2457–2458

28.

Zhang JH, Chen JJ (2006) Mechanism of protection of ulinastatin on lung injury during cardiopulmonary bypass. J Clin Pulm Med 21(7):1261–1263

29.

Xu QH, Chang KQ, Chen WP et al (2006) Effect of ulinastatin on inflammatory cytokins levels in bronchoalveolar lavage fluid and pulmonary function in patients undergoing cardiopulmonary bypass. Chin Circ J 21(4):297–300

30.

Yang GDA, Li J, Zhang J, Zhang MZ (2013) Meta-analysis of the clinical efficacy of the septis by treatment of ulinastatin. Zhejiang J Clin Med 15:197–199

31.

Qiu Y, Lin J, Yang Y et al (2015) Lack of efficacy of ulinastatin therapy during cardiopulmonary bypass surgery. Chin Med J 128:3138–3142PubMedPubMedCentralCrossRef

32.

Inoue K, Takano H (2010) Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs 19(4):513–520PubMedCrossRef

33.

Song J, Park J, Kim JY et al (2013) Effect of ulinastatin on perioperative organ function and systemic inflammatory reaction during cardiac surgery: a randomized double-blinded study. Korean J Anesthesiol 64:334–340PubMedPubMedCentralCrossRef

34.

Leng YX, Yang SG, Song YH et al (2014) Ulinastatin for acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. World J Crit Care Med 3:34–41PubMedPubMedCentralCrossRef

35.

Liu D, Yu Z, Yin J et al (2017) Effect of ulinastatin combined with thymosin alpha1 on sepsis: a systematic review and meta-analysis of Chinese and Indian patients. J Crit Care 39:259–266PubMedCrossRef

36.

Boomer JS, To K, Chang KC et al (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306:2594–2605PubMedPubMedCentralCrossRef

37.

Prashant A, Vishwanath P, Kulkarni P et al (2013) Comparative assessment of cytokines and other inflammatory markers for the early diagnosis of neonatal sepsis-a case control study. PLoS ONE 8:e68426PubMedPubMedCentralCrossRef

38.

Pan Y, Fang H, Lu F et al (2017) Ulinastatin ameliorates tissue damage of severe acute pancreatitis through modulating regulatory T cells. J Inflamm (Lond) 14:7CrossRef

39.

Cao Y, Yang T, Yu S et al (2013) Relationships of adiponectin with markers of systemic inflammation and insulin resistance in infants undergoing open cardiac surgery. Mediators Inflamm 2013:187940PubMedPubMedCentralCrossRef

40.

Oh SY, Kim JC, Choi YS et al (2012) Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass. Korean J Anesthesiol 62:148–153PubMedPubMedCentralCrossRef

41.

Han D, Shang W, Wang G et al (2015) Ulinastatin and thymosin alpha1-based immunomodulatory strategy for sepsis: a meta-analysis. Int Immunopharmacol 29:377–382PubMedCrossRef

42.

He QL, Zhong F, Ye F et al (2014) Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Biomed Res Int 2014:630835PubMedPubMedCentral

43.

Lin Y, Zhu X, Liu F et al (2011) Analysis of risk factors of prolonged intensive care unit stay of critically ill obstetric patients: a 5-year retrospective review in 3 hospitals in Beijing. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 23:449–453PubMed

44.

Joskowiak D, Kappert U, Matschke K et al (2013) Prolonged intensive care unit stay of patients after cardiac surgery: initial clinical results and follow-up. Thorac Cardiovasc Surg 61:701–707PubMedCrossRef

Titel: Effect of ulinastatin on interleukins and pulmonary function in bypass patients: a meta-analysis of randomized controlled trials
verfasst von: G. He
Q. Li
W. Li
Y. Ruan
X. Xiong
X. Song
F. Zeng
Publikationsdatum: 20.08.2018
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 4/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-018-4732-0

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Kardiovaskuläre Notfälle in COVID-19-Zeiten – so gehen Sie weiter vor

Sex-specific aortic root anatomy in patients with bicuspid aortic valve undergoing TAVR in a Chinese cohort

Arrhythmias and sudden cardiac death in the COVID-19 pandemic

Initial resolution of the COVID-19 pandemic in China—can the virus return?